Autologous peripheral blood stem cell

Harter C, Schulze B, Goldschmidt H, Benner A, Geiss HK, Hoppe-Tichy T et al. Piperachlin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or foUowing autologous peripheral blood stem cell transplantation a prospective randomized trial. Bone Marrow Transplant 2006 37 373-79. [Pg.749]

Reichardt, V. L., Okada, C. Y, Liso, A., Benike, C. J., Stockert-Goldstein, K. E., Engleman, E. G., Blume, K. G., and Levy, R. 1999. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma A feasibility study. Blood 93 2411-2419. [Pg.337]

Guidance for Industry Cell Selection Devices for Point of Care Production of Minimally Manipulated Autologous Peripheral Blood Stem Cells (PBSCs)... [Pg.755]

Garrido SM, Chauncey TR. Neuroleptic malignant syndrome following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998 21(4) 427-8. [Pg.246]

Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999 24(8) 897-902. [Pg.369]

The infusion of dimethylsulfoxide-cryopreserved autologous peripheral blood stem cells has been associated with a number of infusion-related adverse effects (4). Severe reversible encephalopathy was experienced by two patients after infusion of peripheral blood stem cells cryopreserved in 10% dimethylsulfoxide. In one patient, reduction of the plasma dimethylsulfoxide concentration by plasmapheresis resulted in marked improvement in encephalopathy (5). The presence of renal insufficiency may have predisposed to the development of neurological toxicity by delaying the excretion of dimethylsulfoxide and its metabolites. Other cases of dimethylsulfoxide-induced encephalopathy have been described (6-8). [Pg.1132]

Kessinger A, Schmit-Pokorny K, Smith D, Armitage J. Cryopreservation and infusion of autologous peripheral blood stem cells. Bone Marrow Transplant 1990 5(Suppl l) 25-7. [Pg.1132]

Sawada M, Tsurumi H, Kara T, Goto H, Yamada T, Oyama M, Moriwaki H. Graft failure of autologous peripheral blood stem cell transplantation due to acute metabohc acidosis associated with total parenteral nutrition in a patient with relapsed breast cancer. Acta Haematol 2000 102(3) 157-9. [Pg.2719]

Most hematological adverse effects associated with trimethoprim have been reported with co-trimoxazole. These include macrocytic and megaloblastic anemia, aplastic anemia, neutropenia, hypersegmentation of leukocytes, thrombocytopenia, and pancytopenia (12,61-63,75-79). Sulfonamides alone have not been associated with folate deficiency, but in combination with trimethoprim they can deplete folate stores in patients with preexisting deficiency of folate or vitamin B12 (80). Treatment with co-trimoxazole can impair the function of mobilized autologous peripheral blood stem cells (81). [Pg.3512]

Fuchs M, Scheid C, Schulz A, Diehl V, Sohngen D. Trimethoprim/sulfamethoxazole prophylaxis impairs function of mobilised autologous peripheral blood stem cells. Bone Marrow Transplant 2000 26(7) 815-16. [Pg.3521]

Between September 1995 and November 2000, 70 patients were vaccinated after autologous peripheral blood stem cell transplantation (ASCT ) with one of two formulations of Theratope (Biomira, Edmonton, Alberta, Canada) coupled with Detox B SE (Detox B) (Corixa, Hamilton, MT). The difference between the two formulations was that the later one has an increased ratio of STn conjugated to KLH compared to the first formulation. The vaccination schedule for the two different formulations was previously published as well as medical treatment history of ASCT patients 18). [Pg.199]

Holmberg L. A. Demirer T. Rowley S. et al. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage 111/lV ovarian cancer. Bone MarrQw ram lanl, 22, 651-659. [Pg.213]

Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation in severe multiple sclerosis. Blood 2003 102 2364-2372. [Pg.1021]

Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma results of a multicenter randomized controlled trial. J Clin Oncol 2001 19 3771-3779. [Pg.2556]

COLLECTION OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS PROSPECTIVELY... [Pg.461]

Krause SW, Rothe G, Gnad M, Reichle A, Andreesen R (2003) Blood leukocyte subsets and cytokine profile after autologous peripheral blood stem cell transplantation. Ann He-matol 82 628-636... [Pg.143]

Bachier C, Potter J, Potter G, Sugay R, Shaughnessy P, Chan K, et al. High white blood ceU concentration in the peripheral blood stem ceU product can induce seizures during infusion of autologous peripheral blood stem cells. Biol Blood Marrow Transpl 2012 18(7) 1055-60. [Pg.502]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...